Is AOD-9604 Legal in Kentucky?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment (residues 176-191) of human growth hormone (hGH). Researchers isolated this C-terminal segment because it appeared to replicate hGH's lipolytic effects without driving IGF-1 elevation or causing significant insulin resistance. Epitope-targeted peptide design of this kind is well-described in the structural literature.

Origin and Mechanism

The peptide was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) under the name Tyr-hGH 177-191. Early animal studies showed dose-dependent reductions in body fat in obese rodent models. A 2001 study published in the American Journal of Physiology found that AOD-9604 reduced fat mass in obese Zucker rats without detectable effects on blood glucose or IGF-1 concentrations.

Human Clinical Data

Phase II and Phase III human trials (the GHRP series sponsored by Metabolic Pharmaceuticals) enrolled several hundred obese adults. Results were modest. A 12-week, placebo-controlled Phase IIb trial found approximately 1.4 kg greater weight loss versus placebo, a difference that did not reach the threshold regulators require for drug approval. The FDA's Center for Drug Evaluation and Research summarizes its evidentiary standards for weight-loss drugs in its 2007 guidance document. Metabolic Pharmaceuticals ultimately discontinued its New Drug Application (NDA) program, leaving AOD-9604 without an approved indication anywhere in the world.

The Federal Legal Framework

Understanding AOD-9604's legality in Kentucky starts at the federal level, because federal law preempts state law on drug scheduling and compounding.

FDA Approval Status

AOD-9604 has never received FDA drug approval. Under 21 U.S.C. § 355, any substance marketed as a drug that lacks approval is unlawful to distribute in interstate commerce. The FDA maintains a searchable database of approved drug products at its Orange Book portal. AOD-9604 does not appear there.

GRAS Designation as a Food Ingredient

In 2014, the FDA acknowledged AOD-9604's Generally Recognized as Safe (GRAS) status as a food ingredient under GRAS Notice No. GRN 000237 for use in foods. The FDA GRAS notice inventory lists this acknowledgment publicly. GRAS status applies to food use only. It does not authorize marketing the substance as a therapeutic drug or as a compound intended to treat, cure, or prevent disease.

DEA Scheduling

AOD-9604 is not listed in any schedule under the Controlled Substances Act (CSA). The DEA's current scheduling list is maintained at its diversion control division. Absent scheduling, possession of the raw peptide is not a criminal offense under federal drug law on its own, though selling it with drug claims triggers FDA enforcement authority under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The FDA Bulk Peptide Compounding Problem

This is where the law becomes genuinely restrictive. In 2023, the FDA finalized its review of bulk drug substances that may be used in compounding under Section 503A of the FD&C Act. AOD-9604 was placed on the Category 2 list, meaning the FDA found insufficient evidence of clinical utility to nominate it for Category 1 (permitted use). The FDA's full 503A bulks list and its Category 2 explanations are published on the agency's compounding page.

Placement on Category 2 does not make compounding automatically illegal in every circumstance, but it does signal that FDA considers the clinical evidence base inadequate and may take enforcement action against pharmacies that compound AOD-9604 routinely or in large batches. Section 503B outsourcing facilities face a stricter standard; they may only compound substances on the 503B bulks list, and AOD-9604 does not appear there.

The practical outcome for patients: a 503A retail compounding pharmacy in Kentucky could, in principle, prepare AOD-9604 for a specific patient under a valid prescription, but doing so while the substance sits on Category 2 exposes the pharmacy to FDA scrutiny. Many licensed compounding pharmacies have responded by declining to compound Category 2 peptides until the FDA resolves their status through formal rulemaking. The FDA's guidance on insanitary conditions and compounding enforcement describes the agency's risk-based approach to pharmacy inspections.

Kentucky State Law and Regulatory Framework

Kentucky has no independent statute that specifically prohibits or permits AOD-9604. State-level analysis therefore focuses on three overlapping bodies of law.

Kentucky Board of Pharmacy

The Kentucky Board of Pharmacy regulates all pharmacies and pharmacists in the Commonwealth under KRS Chapter 315. The Board requires that compounding pharmacies comply with USP standards, including USP Chapter 795 (non-sterile preparations) and USP Chapter 797 (sterile preparations), which govern the environmental, testing, and documentation requirements for any compounded product. USP publishes its current compounding chapters at its official standards portal. A pharmacy that compounds AOD-9604 without meeting these standards faces state licensing consequences independent of any FDA action.

Kentucky Medical Practice Act

Physicians in Kentucky operate under KRS Chapter 311. A licensed Kentucky physician may prescribe a compounded preparation when a commercially available FDA-approved product does not meet a specific patient's medical need. The FDA's own guidance on the medical necessity standard for compounding clarifies that a prescriber must document why the compounded product is needed. Because no FDA-approved AOD-9604 product exists, a physician prescribing it must document a clinical rationale. The Kentucky Board of Medical Licensure (KBML) could investigate prescribing patterns it considers outside the standard of care.

Kentucky Controlled Substances Act

AOD-9604 does not appear in Kentucky's controlled substances schedules, which mirror federal CSA schedules with some additions. Kentucky's controlled substances statute is codified at KRS 218A. Possession of AOD-9604 without drug claims attached is therefore not a state criminal offense. Selling it with therapeutic claims while it lacks drug approval, however, could violate the Kentucky Consumer Protection Act in addition to federal law.

Research-Chemical Vendors and Online Sources

Searching online for AOD-9604 produces dozens of vendors selling it labeled "for research use only" or "not for human consumption." These labels do not create a legal shield.

Why "Research Use Only" Labeling Is Not a Safe Harbor

The FDA treats these labels as pretextual when the vendor's marketing context makes clear the product is intended for human use. The FDA has issued warning letters to multiple peptide vendors on exactly this basis. Purchasing from these vendors means receiving an unverified product with no certificate of analysis reviewed by a licensed pharmacist, no confirmed peptide purity, and no dosing oversight from a licensed prescriber.

Contamination and Purity Risks

Independent testing of peptides sold through gray-market research channels has found peptide content that diverges significantly from labeled amounts. A 2018 analysis published in the journal Drug Testing and Analysis examined the purity of peptides sold online and found that fewer than 50% of tested samples matched their labeled content within acceptable analytical variance. For a peptide administered by subcutaneous injection, purity matters clinically.

How to Get AOD-9604 Legally in Kentucky

The only pathway that keeps a Kentucky patient on the correct side of both federal and state law involves three steps.

Step 1: Obtain a Prescription from a Licensed Kentucky Physician

A physician or nurse practitioner licensed in Kentucky must evaluate the patient, document the clinical indication, and issue a valid prescription. Telehealth prescribing is legal in Kentucky for non-controlled substances following the state's telehealth parity law. The Centers for Medicare and Medicaid Services summarizes telehealth prescribing standards that states like Kentucky have largely adopted. The physician must maintain a prescriber-patient relationship and document why AOD-9604 (as a compounded preparation) is appropriate for this individual.

Step 2: Use a Licensed 503A Compounding Pharmacy

The prescription must be filled at a pharmacy licensed by the Kentucky Board of Pharmacy. That pharmacy must hold current good manufacturing practice (CGMP) compliance or at minimum meet USP 797 standards for sterile injectables. The FDA's list of registered 503B outsourcing facilities is publicly searchable, though AOD-9604 is not currently on the 503B bulks list. Patients should ask the pharmacy for its current inspection record and certificate of analysis for the specific batch.

Step 3: Understand the Residual Risk

Even following these steps, the patient and prescriber are operating with a substance on the FDA's Category 2 list. The FDA's compounding compliance policy guidance makes clear that Category 2 placement does not guarantee enforcement forbearance. Prescribers should document clinical rationale thoroughly. Patients should understand that insurance will not cover a non-approved compounded peptide and that the regulatory status could change, restricting access further.

What Clinicians Are Saying

The Endocrine Society's position on peptide therapies outside FDA approval channels is cautious. The Society's 2019 clinical practice guideline on growth hormone use states: "We recommend against the use of GH or GH secretagogues in healthy adults for anti-aging or body composition purposes outside of clinical trials." The full guideline is available via the Journal of Clinical Endocrinology and Metabolism. AOD-9604 is not a GH secretagogue, but it is a GH fragment, and the Endocrine Society's broader caution about non-approved GH-related peptides applies by analogy.

The American Association of Clinical Endocrinology (AACE) similarly cautions that off-label prescribing of peptides should be reserved for situations in which approved therapies have failed and clinical evidence supports a reasonable benefit-to-risk assessment. AACE's clinical practice guidelines are indexed at its official publication portal. Prescribers in Kentucky would be wise to document this analysis in the medical record.

What Happens If Regulations Change

The FDA's peptide compounding rulemaking is ongoing. The agency has solicited comments on which Category 2 substances should be moved to Category 1 based on new evidence. Federal Register dockets for compounding rulemaking are publicly accessible. If AOD-9604 were ever moved to Category 1, compounding it would become substantially less legally precarious for both pharmacies and prescribers. Conversely, formal prohibition would close the 503A pathway entirely.

Monitoring the FDA's compounding docket is not optional for prescribers who include AOD-9604 in their clinical practice. The docket is updated when public comments are submitted and when the agency issues interim final rules.

Summary of the Legal Risk Spectrum

Not all uses of AOD-9604 in Kentucky carry identical legal risk. The table below maps the access method to its approximate regulatory risk level.

| Access Method | Federal Risk | Kentucky State Risk | |---|---|---| | Valid Rx + licensed 503A pharmacy | Moderate (Category 2 issue) | Low | | Valid Rx + 503B outsourcing facility | High (not on 503B list) | Low | | Online "research chemical" purchase | High (FD&C Act violation risk) | Low-Moderate | | No Rx, injectable use | High | Low-Moderate |

The FDA's overview of how the FD&C Act applies to drug compounding is the foundational document for understanding these distinctions.